Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0172


Improving Pancreatic Cancer Treatment with Combinatorial Chemotherapy Regimen and Erlotinib.

Prof. Odysseas Zoras, M.D, PhD.

Affiliation: Professor Odysseas Zoras, Department of General Surgery, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Crete, Greece.


Since there is no abstract available we provide the first paragraph.

Chemotherapy with gemcitabine has been the standard treatment of patients with metastatic pancreatic cancer. A more aggressive combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was proven more effective although at a higher toxicity than gemcitabine in a phase 3 trial published in the NEJM 2011 May issue. Targeting pancreatic cancer cells with EGFR signalling pathways-blocking drugs could provide a further survival improvement. Is erlotinib, a tyrosine kinase inhibitor, such a safe and effective drug?

(Citation: Gastric & Breast Cancer 2011; 10(3): 151-153)



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 28 June 2011